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ABSTRACT
Macula lutea, the yellow spot or fovea centralis in eye, serves the distinctive central vision in perceiving visual cues and contributing to task 
performance. Impaired visual acuity, in later years in life, compromises safety, productivity, and life quality. Carotenoid pigment content declines 
with cumulation of light-induced damage through aging process in the retina. The progression of resultant macular degeneration is aggravated by 
oxidative stress, inflammation, raised blood sugar, and vasculopathy associating aging. Senescent dry degeneration involves drusen (a compound of 
glycolipid and glycol-conjugate core) deposition that impairs metabolic connectivity of upper layers of retina with choroid. Degeneration of retinal 
pigment epithelium and photoreceptors thus results. The late more severe form of age-related macular degeneration (AMD), involves factors inducing 
choroidal neovascularization. Leaky neocapillaries speed degenerative process of the retina. Most age-related pathologies are initiated by metabolic 
disruptions and AMD shares features of systemic atherosclerosis. An aberrant tissue response to free radical stress, vasculopathy, and local ischemic 
underlies AMD pathogenesis. There is no specific treatment modality and prudent strategy in prophylaxis only. Early diagnosis and proper control of 
environmental and lifestyle factors are strived by newer biomedical understanding, which is briefly reviewed.
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INTRODUCTION
Prevalence of age-related macular degeneration (AMD), mainly 
responsible for post middle age loss of vision is found around 2-5% in 
people above 70 years age in India [1]. Global population above 50 year 
age constitutes only 20% but carries 80% of blind burden. Most of 
the blind people live in developing countries. 90% of all cases of AMD 
are made by dry atrophied form of disease and Caucxasian race is 
more vulnerable. The aggressive neovascularizing form makes minor 
10% prevalence, but mostly responsible for blindness and has greater 
prevalence in underdeveloped parts of the world. AMD stands second 
to diabetes as a cause of severe vision loss from the 5th decade of life 
onward.
Both AMD and diabetic retinopathy involve breakdown of blood-
retinal barrier (BRB). The diabetic retinopathy initially affects inner 
retinal layers of endothelium. Contrastingly, AMD initially affects outer 
retina at chorioretinal interface in the retinal pigment epithelium 
(RPE). Neovascularization in choriocapillaries may subsequently 
invade retina. The retinal tissue has a high metabolism and oxygen 
consumption, with abundant content of polyunsaturated fatty acids. 
Retina is exposed to light, a strong oxidizing factor. Typically, the macula 
area suffers photochemical damage with generation of excess of reactive 
oxygen species (ROS). Around 3% of diagnosed diabetes patients bear 
retinopathy but have much less incidence of AMD than non-diabetic 
population [2]. The damaged BRB of the inner layer in diabetics appears 
to signal upregulated transport function of outer layer BRB in RPE. This 
delays neovascularization that drives AMD progression [3].
Pathogenesis
Photochemical damage due to oxidative stress is the hallmark of AMD. 
Dry form of AMD is characterized by drusen deposits. These impair 
metabolic connectivity of choroid and upper layers of the macula, 
resulting in degeneration of RPE and photoreceptors (PR). Wet form 
of AMD involves choroid neovascularizing factors. The consequent 
increased fluid leaks injure RPE and PRs further. Lipids accumulate 
in the Bruch’s membrane during the ordinary process of aging. The 
membrane thickens and is devoid of protective antioxidant enzymes. 
Lipids cause stimulation of accumulating macrophages toward 
production of vascular endothelial growth factor (VEGF). Inflammation 
sets choroidal neovascularization to eliminate molecules perceived 
as injurious to RPE and PRs. This proves counterproductive. Several 
bioactive mediators and alternate complement pathway sustain the 
chronic inflammation. The spread of Bruch’s membrane leads to 
early and late forms of AMD. Derangements are implied in multiple 
physiological pathways [4].
Primary lesion appears in RPE where molecular debris accumulates 
straining cells. Extrusion of debris and accumulation in Bruch’s 
membrane as drusen aggregates, as well as under basal lamina 
occur next. Progressive degeneration of RPE and PRs continues. 
Leakage from neovascularization membrane invading the debris 
worsens the pathology. New vessels arising from macular disc cause 
vitreous retraction. The pull may cause vitreous hemorrhages, retinal 
detachment, etc. Serous or hemorrhagic leaks elevate the neurosensory 
RPE, resulting in dysmorphic vision, scotoma, blurring, and decline of 
central vision.
PATHOGENIC DETERMINANTS IN AGING PHENOMENA
Aging disorders are cumulative outcome of multiple defective cellular 
mechanisms and metabolic pathways. Environmental and lifestyle 
factors are implicated as well. Metabolism is crucially linked to initiation 
of age-related maladies. The RPE is impacted adversely by oxidized 
cholesterol moieties. Mitochondrial function is deranged, increasing 
apoptosis. The complement system is activated, and there is increased 
expression of VEGF in endothelium. The complement system plays 
a role in drusen formation as well as neovascularization in AMD. The 
accompanying endothelial damage and dysfunction allow formation of 
atheromatous plaque in systemic atherosclerosis. Local and systemic 
complement activity plays role in both atherosclerosis and AMD. Specific 
polymorphism “Y402H” of complement inhibitor factor H is associated 
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with increased incidence of AMD and atherosclerosis [5-8]. The 
molecular composition of drusen is highly similar to an atheromatous 
plaque. Oxidant stress and local ischemia underlie the pathogenesis in 
both.
Endothelial dysfunction
Vascular endothelium supports integrity and stability of circulation 
homeostasis via production of various bioactive modulators and 
hormones [9,10]. Dysfunction of endothelium compromises the 
circulatory homeostasis and preservation of organ functions. AMD 
represents local manifestation of systemic vascular dysfunction. 
Sustained subclinical inflammation is triggered by ROS, generated in 
attempt to eliminate some persisting irritant in the system. The process 
of such inflammaging is obvious in AMD [11].
Endothelial dysfunction is indeed defensive activation. There is 
upregulated expression of pro-inflammatory molecules. Circulatory 
impedance during perturbed states is avoided by synthesis of nitric 
oxide (NO) from endothelial nitric oxide synthase (eNOS) enzyme. 
Excess oxidative stress uncouples function of eNOS, and the NO is 
transformed to peroxynitrite radical in combination with superoxide 
anions. Endothelial dysfunction is NO deficient state [12], inflicted by 
intracellular oxidant stress [13].
Chronic inflammatory state
Chronic inflammation occurring in drusen implicates cellular and 
humoral inflammatory and immune constituents [14]. Antioxidant 
defense is depleted in the aged, making them vulnerable to the 
occurrence of AMD [15]. Inflammatory cytokines in the aqueous humor 
are found increased through all stages of AMD. The persisting irritation, 
as well as pro-inflammatory mediator, contributes to endoplasmic 
reticulum (ER) stress in exposed vascular endothelium. The 
homeostatic cleansing and maintenance tasks of ER get compromised. 
ER stress promotes VEGF expression and angiogenesis, the basis for 
neovascularization [16].
Activation, injury, or apoptosis of vascular endothelial cells release 
submicron sized microparticles in circulation. These are seen in 
chronic cardiovascular, cerebrovascular, renal, and metabolic disorders 
as well as in AMD [17]. The particles are integral components of 
inflammation, vascular injury, angiogenesis, and thrombosis [18]. 
Levels of van Willebrands factor, fibrinogen, and plasminogen 
activator inhibitor type 1 are increased in atherosclerosis as well as in 
AMD [19,20]. Advanced glycation end-product levels are also elevated 
in AMD [21] as also lipid peroxide levels [22,23]. Both are causal to 
endothelial dysfunction. Raised plasma level of C-reactive protein 
(CRP) is a constant feature of AMD [24]. Intraocular inflammation in of 
neovascularized AMD is marked by elevated endothelin-1 levels [25]. 
Systemic atherosclerosis is characterized by generalized complement 
activation [6,7], which is established risk factor for AMD [8]. Retinal 
autoantibodies that occur normally in 10% population are elevated in 
most AMD patients [26]. Increased anticytomegalovirus IgG antibody 
titer is found to significantly associate with AMD [27]. Significant 
association of AMD with periodontal inflammation is reported as 
well  [28]. All these suggest autoimmunity perspectives in pathogenesis.
Sustained inflammation is a crucial pathogenic determinant of 
AMD. CRP elevation is more than just inflammatory biomarker and 
inhibits eNOS expression depleting NO availability. CRP also increases 
angiotensin 1 receptor expression, and consequent increased ROS 
formation, with further inactivation of NO. The endothelial progenitor 
cell (EPC) number and activity are also compromised by CRP. Raised 
concentration of cellular adhesion molecule in drusen suggests activity 
of macrophages gathering around. The adhesion molecules also reveal 
choroidal vascular inflammatory disorder [29]. The risk factors that 
promote atherosclerosis and cardiovascular disease also contribute 
AMD risk [30]. Patients bearing AMD have increased the occurrence of 
stroke and myocardial infarction [31].
Oxidant stress
Normally, only 1% of oxygen destined for mitochondrial respiration 
leak out as superoxide. The proportion increases markedly with 
aging, amid depleted state of antioxidant protection. Same scenario 
manifests with heightened lipid peroxide burden and lowered NO 
availability in AMD [32]. Amid reduced ocular perfusion in the aged, 
RPE dysfunction leads to risk of AMD [33]. There is decline in EPC 
function, parallel with decreased the physical activity of the aged, which 
may be reversed as prevention strategy [34]. Critical to the occurrence 
of vascular impairment is the increased activity of transcription factor 
NF-kappa-B in the aged people [35]. The majority of AMD sufferers 
give positive family history. Smoking is singularly the most provocative 
lifestyle factor for AMD. Circulation disorders, arteriosclerosis, angina, 
myocardial infarction, and stroke are proven secondary risk factors for 
AMD. Decreased retinal perfusion implies altered pericyte function, 
increased blood viscosity, altered fibrinolytic activity. Vasoocclusion 
would cause tissue hypoxia upregulating the mechanisms for 
neovascularization [36]. Obesity, the leading component in metabolic 
syndrome, is independent risk factor for retinopathy [37]. The 
hyperleptinemia increases oxidant stress [38]. Oxidant stress causes 
overexpression of VEGF, the key neovascularizing molecule in AMD [39].
PREVENTION
Preventive measures against AMD have to target the shared mechanisms 
of chronic inflammatory diseases, e.g., cardiovascular disorders, 
obesity, diabetes, hypertension, etc. [40]. Lifestyle modification 
must include smoking cessation, which increases oxidant stress and 
blood coagulability and reduces protective high-density lipoprotein 
cholesterol [41,42]. Nicotine is detrimental to antiangiogenic factor 
production by RPE while stimulates VEGF formation directly [43]. 
Physical activity improves expression of eNOS and NO availability, as 
well as expression of antioxidant superoxide dismutase enzymes [44]. 
Dose-dependent reduction in AMD risk is reported following physical 
exercise [45]. Physical exercise also improves mitochondrial function 
and activity of EPC [46,47]. Both such consequences are good for 
vascular health.
Nutrients
Role of micro and macronutrients in modifying individual risk factors 
are widely studied. Carotenoids are present in macular pigment and 
exert antioxidant influence on PR cell layer through filtering blue 
light, which mediates light injury. Polyphenolic antioxidants contained 
in green vegetables and carotenoids in colored fruits and had shown 
good preventive promise. Carotenoid lutein suppresses NF-kappa-B 
activation and systemic inflammation, choroidal neovascularization, 
and retinal ischemia [48]. Lutein and zeaxanthin help filtering injurious 
blue light and quench free radicals [49]. Dietary intakes of lutein and 
zeaxanthin are found low in most AMD patients [50]. Supplementation 
of such carotenoids may be prudent preventive measure in the aging 
individuals.
High glycemic index foods increase formation of the advanced 
glycation end products (AGE), which accumulate in tissue causing the 
ER stress [51]. Avoidance of such foods appears to offer preventive 
benefit [52]. Weight reduction in overweight individuals reduces risk of 
AMD [53]. Calorie restriction to half of the ad-libitum intake, improves 
NO production and function, improved mitochondrial bioenergetics, and 
reduced ROS generation. The activity of silent information regulator 1 
is also enhanced and the endothelial function is benefited via multiple 
ways. Calorie restriction thus has proven prevention value [54].
Favorable influence of Omega-3 fatty acids, rich in linseed, olive, 
and fish oil on vascular and other degenerative processes in 
chronic inflammatory state is well known. Peroxisome proliferator-
activated receptor (PPAR) gamma receptor mechanisms, linked to 
lipid metabolism, also are found to mediate protection from AMD. 
This is apparent from the favorable effects of regular consumption 
of docosahexaenoic acid and eicosapentaenoic acid (fish oil) [55]. 
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Increasing understanding on biological roles of vitamin D supplement 
in aging the individual is relevant also to prevention of AMD [56]. Folate 
deficiency is linked to the occurrence of hyperhomocysteinemia, with 
pro-inflammatory influence. Combined folate with vitamin B12, B6 
supplement in elderly shows preventive benefits against AMD [57].
Zinc supplement offers excellent biological rationale [58]. That checks 
activation of the complement cascade, with established pathogenic 
role [59,60]. Dietary L-arginine supplement is used to boost NO 
production. It is shown to be relevant to AMD prevention [61,62]. Patients 
with AMD are deficient in coenzyme Q profile, and its supplementation 
helps delaying disease progression [63,64]. The unique, calorie 
restriction-mimetic potential of resveratrol, has generated interest in 
supplementation trials for preventing light-induced retinal damage and 
endothelial dysfunction in AMD [65,66]. The patients with AMD exhibit 
profoundly deficient profile of melatonin, compared to normal age-
matched fellows [67,68]. Melatonin supports cell vitality via telomerase 
enzyme function in RPE. A boost to melatonin profile may be preventive 
for AMD.
PHARMACEUTICAL PREVENTION
Pharmacological prevention should aim at suppressing free radical 
stress, improving NO production and thus correcting endothelial 
dysfunction. This is systemic objective in prevention of aging-associated 
disorders [69]. Overactive renin-angiotensin-aldosteron system is 
implicated in pro-inflammatory state, and its control has prevention 
value [70]. Angiotensin receptor blockade (ARB) prevents choroidal 
neovascularization in AMD [71]. Telmisartan, an ARB also is stimulant 
to PPAR gamma, boosting the preventive beneficence [72]. Angiotensin 
receptors mediate nicotinamide adenine dinucleotide phosphate 
oxidase activation and critically enhance the generation of oxidant 
stress that may be suppressed specifically by ARB drugs [73-76].
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor lipid-
lowering drugs, the statins, possess a variety of antiaging actions [77]. 
Statins correct the NO versus superoxide imbalance and thus improve 
endothelial function. They inhibit leukocyte-endothelium adhesion/
interaction and that damages retina and repress angiogenesis. Patients 
with coronary artery disease are taking statin exhibit 5-fold reduced 
the risk of developing AMD [78]. Preventive potential of statins against 
AMD is proven [79,80].
Preventive promise is also shown by drugs inhibiting endothelial 
uptake of oxidized lipoproteins [81]. Trimetazidine, an agent, 
promoting preferential utilization of glucose over fat, for use as fuel, 
reduces oxidative stress and ischemic injury [82]. Novel newer beta-
adrenoceptor blockers carvedilol and nebivolol, improve mitochondrial 
function [83]. PPAR gamma agonists also exhibit such effect [84]. Both 
these drug classes inhibit oxidant stress, improve NO availability and 
function. Current consensus favors the development of agents that 
share such actions, and additionally, may break the peroxynitrite 
radical [74].
Alagebrium, a drug breaking the AGEs may correct endothelial 
dysfunction [85]. An antagonist of endothelin, Bonestan, also inhibits 
neovascularization in AMD [25]. Novel pharmacological agents being 
evaluated for preventive potential against AMD include an antagonist 
of serotonin receptor 1a [86], an antagonist of tumor necrosis factor 
alfa [87], as well as well-known antioxidant n-acetylcysteine [88]. 
Critical significance of the activation of alternate complement pathway 
in chronic inflammation states has prompted testing of inhibitors 
toward stalling neovascularization and retinal damage in AMD [89].
PUBLIC HEALTH PERSPECTIVES
As per the WHO projection, AMD would comprise 7% and diabetic 
retinopathy 4% of blinding disorders of eye by 2020 [90]. Low power 
laser ablation conjunct with verteporfin (photosensitizer), render 
uncertain benefits in a very small fraction of AMD cases. Intravitrious 
injections of anti-VEGF agents are practically most demanding and 
again limited in benefit. Any surgical interventions would need services 
of highly skilled vitreoretinal surgeons, again promising no certain 
benefit. These are mostly indicated in the neovascularizing form of 
AMD, the late hopeless stage.
The available primary/secondary prevention through lifestyle options, 
nutraceuticals, and drugs deserves chance in persons above 50 years 
age and bearing cardiovascular risk factors. All individuals diagnosed 
as having AMD at any stage must receive proactive management 
with available remedies. As of now, preventive measures for healthy 
individuals are untested. People’s education and awareness of modify 
able risk factors, e.g., avoidance of smoking, control of obesity appear 
very relevant. A survey revealed that 73% of diabetic retinopathy 
cases and 84% cases with AMD are simply unaware of their serious 
condition [91]. This raises serious public health concern, for regular eye 
checkups, for elderly complaining any deterioration in vision. Definitive 
referral mechanism for care must be available when AMD is detected 
in eye check-ups. Rehabilitation is indispensable need, and depression 
for vision loss must be timely addressed. Techniques for early diagnosis 
and delivery of requisite care, cost reduction in available treatment 
options in community contexts, are crying vistas to address by research 
and developmental health-care policy [92].
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